Pleiotropic effects of statins in atherosclerotic disease: Focus on the antioxidant activity of atorvastatin

Current Topics in Medicinal Chemistry

Volumn 14, Issue 22, 2014, Pages 2542-2551

  Profumo, Elisabetta ^a   Buttari, Brigitta ^a   Saso, Luciano ^b   Riganò, Rachele ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atherosclerosis; Atorvastatin; Endothelial dysfunction; Inflammation; Oxidative stress; Reactive oxygen species

Indexed keywords

ANGIOPOIETIN 2; ATORVASTATIN; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CYTOCHROME P450; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; SUPEROXIDE DISMUTASE; ANTIOXIDANT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ACTIN FILAMENT; ACUTE LUNG INJURY; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CATARACT; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL SYNTHESIS; DEGENERATIVE DISEASE; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FIBRINOLYSIS; HUMAN; HYPOLIPEMIA; INFLAMMATION; LIPID PEROXIDATION; MULTIFACTORIAL INHERITANCE; MUSCLE WEAKNESS; MYALGIA; NEOINTIMA; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; POLYNEUROPATHY; PROTEIN HOMEOSTASIS; PROTEIN PROCESSING; VASODILATATION; VITAMIN BLOOD LEVEL;

ANTIOXIDANTS; ATHEROSCLEROSIS; HEPTANOIC ACIDS; HUMANS; PYRROLES;

EID: 84921829271     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141203130324     Document Type: Article

References (112)

1. Barallobre-Barreiro, J.; Chung, Y.L.; Mayr, M. Proteomics and metabolomics for mechanistic insights and biomarker discovery in cardiovascular disease. Rev. Esp. Cardiol., 2013, 66, 657-661.
2. Ng, C.Y.; Leong, X.F.; Masbah, N.; Adam, S.K.; Kamisah, Y.; Jaarin, K. Heated vegetable oils and cardiovascular disease risk factors. Vascul. Pharmacol., 2014, 61, 1-9.
3. Profumo, E.; Buttari, B.; Rigano, R. Oxidative stress in cardiovascular inflammation: its involvement in autoimmune responses. Int. J. Inflam., 2011, 2011, 295705.
4. Lee, S.; Park, Y.; Zuidema, M.Y.; Hannink, M.; Zhang, C. Effects of interventions on oxidative stress and inflammation of cardiovascular diseases. World J. Cardiol., 2011, 3, 18-24.
5. Madamanchi, N.R.; Vendrov, A.; Runge, M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 29- 38.
6. Badran, M.; Ayas, N.; Laher, I. Cardiovascular complications of sleep apnea: role of oxidative stress. Oxid. Med. Cell Longev., 2014, 2014, 985258.
7. Schirmer, S.H.; Werner, C.M.; Laufs, U.; Bohm, M. Nitric oxidedonating statins: a new concept to boost the lipid-independent effects. Cardio. Res., 2012, 94, 395-397.
8. Favero, G.; Paganelli, C.; Buffoli, B.; Rodella, L.F.; Rezzani, R. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed. Res. Int., 2014, 2014, 801896.
9. Nilsson, J.; Wigren, M.; Shah, P.K. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis. Trends Cardio. Med., 2009, 19, 272-276.
10. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352, 1685-1695.
11. Griendling, K.K.; FitzGerald, G. A. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation, 2003, 108, 2034-2040.
12. Kim, Y.W.; Byzova, T.V. Oxidative stress in angiogenesis and vascular disease. Blood, 2014, 123, 625-631.
13. Schleicher, E.; Friess, U. Oxidative stress, AGE, and atherosclerosis. Kidney Int. Suppl., 2007, S17-26.
14. Lu, J. M.; Lin, P. H.; Yao, Q.; Chen, C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J. Cell Mol. Med., 2010, 14, 840-860.
15. Chakrabarti, S.; Jahandideh, F.; Wu, J. Food-derived bioactive peptides on inflammation and oxidative stress. Biomed Res Int,2014, 2014, 608979.
16. Puddu, P.; Puddu, G.M.; Cravero, E.; De Pascalis, S.; Muscari, A. The emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis. J Biomed Sci, 2009, 16, 112.
17. Galis, Z.S.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94, 2493-2503.
18. Griendling, K.K.; FitzGerald, G.A. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation, 2003, 108, 1912-1916.
19. Kunsch, C.; Medford, R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res., 1999, 85, 753-766.
20. Nilsson, J.; Hansson, G.K. Autoimmunity in atherosclerosis: a protective response losing control? J. Intern. Med., 2008, 263, 464- 478.
21. Frostegard, J.; Wu, R.; Giscombe, R.; Holm, G.; Lefvert, A.K.; Nilsson, J. Induction of T-cell activation by oxidized low density lipoprotein. Arterios. Thromb., 1992, 12, 461-467.
22. Stemme, S.; Faber, B.; Holm, J.; Wiklund, O.; Witztum, J. L.; Hansson, G. K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U S A, 1995, 92, 3893-3897.
23. Matusik, P.; Guzik, B.; Weber, C.; Guzik, T.J. Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice? Thromb. Haemost., 2012, 108, 443-456.
24. Doring, Y.; Manthey, H.D.; Drechsler, M.; Lievens, D.; Megens, R.T.; Soehnlein, O.; Busch, M.; Manca, M.; Koenen, R.R.; Pelisek, J.; Daemen, M.J.; Lutgens, E.; Zenke, M.; Binder, C.J.; Weber, C.; Zernecke, A. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation, 2012, 125, 1673-1683.
25. Van Vre, E.A.; Ait-Oufella, H.; Tedgui, A.; Mallat, Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterios. Thromb. Vasc. Biol., 2012, 32, 887-893.
26. Buttari, B.; Profumo, E.; Mattei, V.; Siracusano, A.; Ortona, E.; Margutti, P.; Salvati, B.; Sorice, M.; Rigano, R. Oxidized beta2- glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood, 2005, 106, 3880-3887.
27. Buttari, B.; Profumo, E.; Capozzi, A.; Facchiano, F.; Saso, L.; Sorice, M.; Rigano, R. Advanced glycation end products of human beta(2) glycoprotein I modulate the maturation and function of DCs. Blood, 2011, 117, 6152-6161.
28. Levy, A.P.; Moreno, P.R. Intraplaque hemorrhage. Curr. Mol. Med., 2006, 6, 479-488.
29. Profumo, E.; Buttari, B.; Saso, L.; Capoano, R.; Salvati, B.; Rigano, R. T lymphocyte autoreactivity in inflammatory mechanisms regulating atherosclerosis. Scientif. World J., 2012, 2012, 157534.
30. Profumo, E.; Buttari, B.; Alessandri, C.; Conti, F.; Capoano, R.; Valesini, G.; Salvati, B.; Rigano, R. Beta2-glycoprotein I is a target of T cell reactivity in patients with advanced carotid atherosclerotic plaques. Int. J. Immunopathol. Pharmacol., 2010, 23, 73-80.
31. Profumo, E.; Buttari, B.; Rigano, R. Oxidized haemoglobin as antigenic target of cell-mediated immune reactions in patients with carotid atherosclerosis. Autoimmun. Rev., 2009, 8, 558-562.
32. Buttari, B.; Profumo, E.; Facchiano, F.; Ozturk, E. I.; Segoni, L.; Saso, L.; Rigano, R. Resveratrol prevents dendritic cell maturation in response to advanced glycation end products. Oxid. Med. Cell Longev., 2013, 2013, 574029.
33. Buttari, B.; Profumo, E.; Segoni, L.; D'Arcangelo, D.; Rossi, S.; Facchiano, F.; Saso, L.; Businaro, R.; Iuliano, L.; Rigano, R. Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic implications in atherosclerosis. Oxid. Med. Cell Longev., 2014, 2014, 257543.
34. Dauchet, L.; Amouyel, P.; Dallongeville, J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. Neurology, 2005, 65, 1193-1197.
35. Voko, Z.; Hollander, M.; Hofman, A.; Koudstaal, P. J.; Breteler, M. M. Dietary antioxidants and the risk of ischemic stroke: the Rotterdam Study. Neurology, 2003, 61, 1273-1275.
36. Brighenti, F.; Valtuena, S.; Pellegrini, N.; Ardigo, D.; Del Rio, D.; Salvatore, S.; Piatti, P.; Serafini, M.; Zavaroni, I. Total antioxidant capacity of the diet is inversely and independently related to plasma concentration of high-sensitivity C-reactive protein in adult Italian subjects. Br. J. Nutr., 2005, 93, 619-625.
37. Valtuena, S.; Pellegrini, N.; Franzini, L.; Bianchi, M. A.; Ardigo, D.; Del Rio, D.; Piatti, P.; Scazzina, F.; Zavaroni, I.; Brighenti, F. Food selection based on total antioxidant capacity can modify antioxidant intake, systemic inflammation, and liver function without altering markers of oxidative stress. Am. J. Clin. Nutr., 2008, 87, 1290-1297.
38. Sartori-Valinotti, J.C.; Iliescu, R.; Fortepiani, L.A.; Yanes, L.L.; Reckelhoff, J. F. Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease. Clin. Exp. Pharmacol. Physiol., 2007, 34, 938-945.
39. Lonn, E.; Yusuf, S.; Dzavik, V.; Doris, C.; Yi, Q.; Smith, S.; Moore-Cox, A.; Bosch, J.; Riley, W.; Teo, K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation, 2001, 103, 919-925.
40. Dahlof, B.; Devereux, R.B.; Kjeldsen, S.E.; Julius, S.; Beevers, G.; de Faire, U.; Fyhrquist, F.; Ibsen, H.; Kristiansson, K.; Lederballe- Pedersen, O.; Lindholm, L. H.; Nieminen, M. S.; Omvik, P.; Oparil, S.; Wedel, H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet., 2002, 359, 995-1003.
41. Del Rio, D.; Agnoli, C.; Pellegrini, N.; Krogh, V.; Brighenti, F.; Mazzeo, T.; Masala, G.; Bendinelli, B.; Berrino, F.; Sieri, S.; Tumino, R.; Rollo, P. C.; Gallo, V.; Sacerdote, C.; Mattiello, A.; Chiodini, P.; Panico, S. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. J Nutr., 2011, 141, 118-123.
42. Thomson, M.J.; Puntmann, V.; Kaski, J. C. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc Drugs Ther., 2007, 21, 195-210.
43. Rached, F.H.; Chapman, M.J.; Kontush, A. An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias. Clin. Pharmacol. Ther., 2014
44. Sirtori, C.R. The pharmacology of statins. Pharmacol. Res.,2014
45. Wang, Z.; Wu, Y.; Wang, H.; Zhang, Y.; Mei, L.; Fang, X.; Zhang, X.; Zhang, F.; Chen, H.; Liu, Y.; Jiang, Y.; Sun, S.; Zheng, Y.; Li, N.; Huang, L. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad. Sci. U S A, 2014, 111, E89-98.
46. Melo, A.C.; Valenca, S.S.; Gitirana, L.B.; Santos, J.C.; Ribeiro, M.L.; Machado, M.N.; Magalhaes, C.B.; Zin, W.A.; Porto, L.C. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin- induced acute lung injury. Int. Immunopharmacol., 2013, 17, 57-64.
47. Sezer, E.D.; Sozmen, E.Y.; Nart, D.; Onat, T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc. Health Risk Manag., 2011, 7, 333-343.
48. Pecoraro, V.; Moja, L.; Dall'Olmo, L.; Cappellini, G.; Garattini, S. Most appropriate animal models to study the efficacy of statins: a systematic review. Eur. J. Clin. Invest., 2014, 44, 848-871.
49. Moja, L.; Pecoraro, V.; Ciccolallo, L.; Dall'Olmo, L.; Virgili, G.; Garattini, S. Flaws in animal studies exploring statins and impact on meta-analysis. Eur. J. Clin. Invest., 2014, 44, 597-612.
50. Murrow, J.R.; Sher, S.; Ali, S.; Uphoff, I.; Patel, R.; Porkert, M.; Le, N.A.; Jones, D.; Quyyumi, A. A. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J. Clin. Lipidol., 2012, 6, 42-49.
51. Zhou, Q.; Liao, J. K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des., 2009, 15, 467-478.
52. Zhou, Q.; Liao, J. K. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ. J., 2010, 74, 818-826.
53. Mooradian, A.D.; Haas, M.J.; Batejko, O.; Hovsepyan, M.; Feman, S.S. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes, 2005, 54, 2977-2982.
54. Castro, P.F.; Miranda, R.; Verdejo, H.E.; Greig, D.; Gabrielli, L.A.; Alcaino, H.; Chiong, M.; Bustos, C.; Garcia, L.; Mellado, R.; Vukasovic, J. L.; Godoy, I.; Lavandero, S. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J. Heart Lung. Transplant, 2008, 27, 435-441.
55. Wassmann, S.; Laufs, U.; Muller, K.; Konkol, C.; Ahlbory, K.; Baumer, A. T.; Linz, W.; Bohm, M.; Nickenig, G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterios. Thromb. Vasc Biol., 2002, 22, 300-305.
56. Guijarro, C.; Blanco-Colio, L.M.; Ortego, M.; Alonso, C.; Ortiz, A.; Plaza, J.J.; Diaz, C.; Hernandez, G.; Egido, J. 3-Hydroxy-3- methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res., 1998, 83, 490-500.
57. Kothe, H.; Dalhoff, K.; Rupp, J.; Muller, A.; Kreuzer, J.; Maass, M.; Katus, H.A. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation, 2000, 101, 1760-1763.
58. Laufs, U.; Marra, D.; Node, K.; Liao, J.K. 3-Hydroxy-3- methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced downregulation of p27(Kip1). J. Biol. Chem., 1999, 274, 21926-21931.
59. Wei, Y.M.; Li, X.; Xiong, J.; Abais, J.M.; Xia, M.; Boini, K.M.; Zhang, Y.; Li, P.L. Attenuation by statins of membrane raft-redox signaling in coronary arterial endothelium. J. Pharmacol. Exp. Ther., 2013, 345, 170-179.
60. Dick, M.; Jonak, P.; Leask, R.L. Statin therapy influences endothelial cell morphology and F-actin cytoskeleton structure when exposed to static and laminar shear stress conditions. Life Sci., 2013, 92, 859-865.
61. de Oliveira, C.V.; Funck, V.R.; Pereira, L.M.; Grigoletto, J.; Rambo, L.M.; Ribeiro, L.R.; Royes, L.F.; Furian, A.F.; Oliveira, M.S. Atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex. Pharmacol. Res., 2013, 71, 1-8.
62. Lei, Q.; Peng, W.N.; You, H.; Hu, Z.P.; Lu, W. Statins in nervous system-associated diseases: angels or devils? Pharmazie, 2014, 69, 448-454.
63. Hernandez-Ojeda, J.; Roman-Pintos, L.M.; Rodriguez-Carrizalez, A.D.; Troyo-Sanroman, R.; Cardona-Munoz, E.G.; Alatorre- Carranza Mdel, P.; Miranda-Diaz, A.G. Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebocontrolled Phase IIa study. Diabetes Metab. Syndr. Obes., 2014, 7, 401-407.
64. Endo, A. A historical perspective on the discovery of statins. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci., 2010, 86, 484-493.
65. Zoungas, S.; Curtis, A.; McNeil, J.; Tonkin, A. Treatment of dyslipidemias and cardiovascular outcomes: the journey so far. Is this the end for statins? Clin. Pharmacol. Ther., 2014
66. Amarenco, P.; Benavente, O.; Goldstein, L.B.; Callahan, A., 3rd; Sillesen, H.; Hennerici, M.G.; Gilbert, S.; Rudolph, A.E.; Simunovic, L.; Zivin, J.A.; Welch, K.M. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke, 2009, 40, 1405-1409.
67. Everett, B.M.; Glynn, R.J.; MacFadyen, J.G.; Ridker, P.M. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation, 2010, 121, 143-150.
68. Vale, N.; Nordmann, A.J.; Schwartz, G.G.; de Lemos, J.; Colivicchi, F.; den Hartog, F.; Ostadal, P.; Macin, S. M.; Liem, A. H.; Mills, E. J.; Bhatnagar, N.; Bucher, H. C.; Briel, M. Statins for acute coronary syndrome. Cochrane Database Syst Rev., 2014, 9, CD006870.
69. Moon, G.J.; Kim, S.J.; Cho, Y.H.; Ryoo, S.; Bang, O. Y. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J. Clin. Neurol., 2014, 10, 140-147.
70. Essig, M.; Nguyen, G.; Prie, D.; Escoubet, B.; Sraer, J. D.; Friedlander, G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res., 1998, 83, 683-690.
71. Hernandez-Perera, O.; Perez-Sala, D.; Navarro-Antolin, J.; Sanchez- Pascuala, R.; Hernandez, G.; Diaz, C.; Lamas, S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest.,1998, 101, 2711-2719.
72. Laufs, U.; La Fata, V.; Plutzky, J.; Liao, J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998, 97, 1129-1135.
73. John, S.; Schneider, M. P.; Delles, C.; Jacobi, J.; Schmieder, R. E. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am. Heart J., 2005, 149, 473.
74. Hilbert, T.; Poth, J.; Frede, S.; Klaschik, S.; Hoeft, A.; Baumgarten, G.; Knuefermann, P. Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells. Biochem. Pharmacol., 2013, 86, 1452-1460.
75. Bustos, C.; Hernandez-Presa, M. A.; Ortego, M.; Tunon, J.; Ortega, L.; Perez, F.; Diaz, C.; Hernandez, G.; Egido, J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll Cardiol., 1998, 32, 2057-2064.
76. Sultan, S.; Hynes, N. Commentary: on the silver jubilee of subintimal angioplasty, how successful are contemporary endovascular therapies in the management of critical limb ischemia? J. Endovasc. Ther., 2014, 21, 254-257.
77. Cenedella, R. J. Cholesterol and cataracts. Surv. Ophthalmol., 1996, 40, 320-337.
78. Chodick, G.; Amital, H.; Shalem, Y.; Kokia, E.; Heymann, A. D.; Porath, A.; Shalev, V. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med., 2010, 7, e1000336.
79. Fong, D. S.; Poon, K. Y. Recent statin use and cataract surgery. Am. J. Ophthalmol., 2012, 153, 222-228 e221.
80. Hippisley-Cox, J.; Coupland, C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ, 2010, 340, c2197.
81. Leuschen, J.; Mortensen, E.M.; Frei, C.R.; Mansi, E.A.; Panday, V.; Mansi, I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol., 2013, 131, 1427-1434.
82. Hoffman, K.B.; Kraus, C.; Dimbil, M.; Golomb, B. A. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One, 2012, 7, e42866.
83. Mansi, I.; Frei, C. R.; Pugh, M. J.; Makris, U.; Mortensen, E. M. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern. Med., 2013, 173, 1-10.
84. Muscogiuri, G.; Sarno, G.; Gastaldelli, A.; Savastano, S.; Ascione, A.; Colao, A.; Orio, F. The good and bad effects of statins on insulin sensitivity and secretion. Endocr. Res., 2014, 1-7.
85. Taylor, F.; Ward, K.; Moore, T. H.; Burke, M.; Davey Smith, G.; Casas, J. P.; Ebrahim, S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev., 2011, CD004816.
86. Barone, E.; Cenini, G.; Di Domenico, F.; Martin, S.; Sultana, R.; Mancuso, C.; Murphy, M. P.; Head, E.; Butterfield, D. A. Longterm high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol. Res, 2011, 63, 172-180.
87. Franzoni, F.; Quinones-Galvan, A.; Regoli, F.; Ferrannini, E.; Galetta, F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol, 2003, 90, 317-321.
88. Roth, B.D. The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog Med Chem,2002, 40, 1- 22.
89. Furberg, C.D. Natural statins and stroke risk. Circulation,1999, 99, 185-188.
90. Jacob, R.F.; Walter, M.F.; Self-Medlin, Y.; Mason, R. P. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein. J. Cardio. Pharmacol., 2013, 62, 160-166.
91. Vishal, T. B. G. K., V.; Parihar, A.; Gupta, S. Pleiotropic effects of statins. Indian Journal of Pharmacology,2005, 37, 77-85
92. Tu, Q.; Cao, H.; Zhong, W.; Ding, B.; Tang, X. Atorvastatin protects against cerebral ischemia/reperfusion injury through antiinflammatory and antioxidant effects. Neural. Regen. Res.,2014, 9, 268-275.
93. Wassmann, S.; Laufs, U.; Baumer, A. T.; Muller, K.; Ahlbory, K.; Linz, W.; Itter, G.; Rosen, R.; Bohm, M.; Nickenig, G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001, 37, 1450-1457.
94. Patel Timir, B.; Patel, L.D.; Patel Tejas, B.; Makawana Sunil, H.; Patel Tushar, R. Effects of atorvastatin as antioxidants in diabetic associated cardiovascular complications. J. Pharma. Sci. Res., 2010, 2, 247-256.
95. Sozer, V.; Uzun, H.; Gelisgen, R.; Kaya, M.; Kalayci, R.; Tabak, O.; Arican, N.; Konukoglu, D. The effects of atorvastatin on oxidative stress in L-NAME-treated rats. Scand J Clin Lab Invest,2013, 73, 591-597.
96. Violi, F.; Loffredo, L.; Musella, L.; Marcoccia, A. Should antioxidant status be considered in interventional trials with antioxidants? Heart, 2004, 90, 598-602.
97. Najah, R.H.M.A.A.; Omran, M.O.A. Antioxidant effect of atorvastatin in type 2 diabetic patients. Pharma. Res., 2010, 1, 53-59.
98. Belcaro, G.; Cornelli, U.; Finco, A. The Carotid Intima-Media Thickness Modification Following Atorvastatin is Bound to the Modification of the Oxidative Balance. J. Cardio. Pharmacol. Ther.,2014
99. Broncel, M.; Bala, A.; Koter-Michalak, M.; Duchnowicz, P.; Wojsznis, W.; Chojnowska-Jezierska, J. Physicochemical modifications induced by statins therapy on human erythrocytes membranes. Wiad Lek, 2007, 60, 321-328.
100. Bellosta, S.; Ferri, N.; Bernini, F.; Paoletti, R.; Corsini, A. Nonlipid- related effects of statins. Ann Med,2000, 32, 164-176.
101. Mason, R.P.; Walter, M. F.; Day, C. A.; Jacob, R. F. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J. Biol. Chem., 2006, 281, 9337-9345.
102. Miyano, K.; Sumimoto, H. Assessment of the role for Rho family GTPases in NADPH oxidase activation. Methods Mol. Biol., 2012, 827, 195-212.
103. Pignatelli, P.; Carnevale, R.; Pastori, D.; Cangemi, R.; Napoleone, L.; Bartimoccia, S.; Nocella, C.; Basili, S.; Violi, F. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation, 2012, 126, 92-103.
104. Babior, B. M. NADPH oxidase: an update. Blood, 1999, 93, 1464- 1476.
105. Mizrahi, A.; Berdichevsky, Y.; Casey, P. J.; Pick, E. A prenylated p47phox-p67phox-Rac1 chimera is a Quintessential NADPH oxidase activator: membrane association and functional capacity. J. Biol. Chem, 2010, 285, 25485-25499.
106. Cangemi, R.; Pignatelli, P.; Carnevale, R.; Nigro, C.; Proietti, M.; Angelico, F.; Lauro, D.; Basili, S.; Violi, F. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes, 2012, 61, 1626-1632.
107. Pratico, D.; Tangirala, R.K.; Rader, D.J.; Rokach, J.; FitzGerald, G. A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med., 1998, 4, 1189- 1192.
108. Carnevale, R.; Pignatelli, P.; Lenti, L.; Buchetti, B.; Sanguigni, V.; Di Santo, S.; Violi, F. LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes. Faseb J., 2007, 21, 927-934.
109. Cangemi, R.; Loffredo, L.; Carnevale, R.; Perri, L.; Patrizi, M.P.; Sanguigni, V.; Pignatelli, P.; Violi, F. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur. Heart J., 2008, 29, 54-62.
110. Perez-Castrillon, J. L.; Vega, G.; Abad, L.; Sanz, A.; Chaves, J.; Hernandez, G.; Duenas, A. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am. J. Cardiol., 2007, 99, 903-905.
111. Najah, R. H. M., A.A.H.; Ammar, R.M.R. Effect of atorvastatin on oxidative stress parameters and lipid profile in type 2 diabetic patients. Inter. Med. J., 2008, 7, 43-49.
112. Danesh, F.R.; Kanwar, Y.S. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. Faseb J., 2004, 18, 805-815.